stockrow
Saturday 7 November 2026
Export TECX’s income statement to Excel — free account
Tectonic Therapeutic, Inc.
TECX Healthcare Biotechnology
- EPS
- −10.3%
- Free cash flow
- −46.7%
- Total debt
- −94.0%
Quarter to June 2026, against a year earlier
20.62
1.20
+6.18%
Follow TECX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (5) | (19) | (46) | (73) | (120) | (119) | (106) | (43) | (58) | (73) | (85) | +35.7% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (5) | (19) | (46) | (73) | (120) | (119) | (106) | (43) | (58) | (74) | (86) | +36.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (2.29) | (8.34) | (3.62) | (2.66) | (3.31) | (2.78) | (2.42) | (33.75) | (6.83) | (4.05) | (4.57) | +6.5% | ||||||
| Cash flow | (1.63) | (7.33) | (2.80) | (2.47) | (2.73) | (2.29) | (2.22) | (32.06) | (6.96) | (3.28) | (3.80) | +8.1% | ||||||
| Capex | 0.00 | (0.17) | (0.14) | (0.06) | (0.03) | (0.06) | (0.01) | (0.22) | (0.02) | (0.01) | (0.01) | n/m | ||||||
| Free cash flow | (1.63) | (7.50) | (2.94) | (2.52) | (2.76) | (2.34) | (2.23) | (32.28) | (6.98) | (3.29) | (3.82) | +8.1% | ||||||
| Book value | (2.25) | (10.35) | 9.09 | 6.78 | 7.02 | 3.95 | 1.72 | (66.69) | 16.58 | 13.72 | 11.80 | n/m | ||||||
| Shares, m | 2 | 2 | 13 | 27 | 36 | 43 | 44 | 1 | 8 | 18 | 19 | +27.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (3) | (16) | (38) | (68) | (99) | (98) | (97) | (41) | (59) | (60) | (72) | +38.0% | |||||
| Capex | — | 0 | (2) | (2) | (1) | (2) | 0 | 0 | 0 | 0 | 0 | (12.0%) | ||||||
| Free cash flow | (3) | (17) | (39) | (69) | (100) | (100) | (97) | (41) | (59) | (60) | (72) | +38.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 4 | 4 | 119 | 182 | 251 | 180 | 87 | (10) | 135 | 248 | 221 | +56.2% | |||||
| Net debt | (5) | (6) | (126) | (187) | (260) | (175) | (78) | (28) | (141) | (254) | (227) | +53.6% | ||||||
| Shareholders’ equity | (5) | (23) | 122 | 186 | 254 | 169 | 75 | (85) | 141 | 251 | 224 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (80.00) | (301.61) | (69.19) | (43.69) | (50.75) | (50.15) | (68.81) | (59.75) | (60.30) | (35.83) | (32.23) | +44.2 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 35.86 | 135.19 | (98.14) | (47.35) | (54.37) | (56.22) | (86.50) | 924.30 | (206.56) | (37.82) | (33.80) | (73.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 34 | 49 | 85 | 121 | 122 | 78 | 13 | 51 | 60 | — | +7.4% | |||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Tectonic Therapeutic, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics, Inc. | $402.1M | — (loss-making) | — | — | n/m | −50.06% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BLSM BlossomHill Therapeutics, Inc. | $392.6M | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| EDIT Editas Medicine, Inc. | $391.6M | — (loss-making) | — (loss-making) | +232.31% (above 0%: growing) | n/m | +40.72% (above 0%: growing) | 100.00% | (156.05%) | Compare |
| ALT Altimmune, Inc. | $383.2M | — (loss-making) | — (loss-making) | +520.00% (above 0%: growing) | n/m | −25.27% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| TECX Tectonic Therapeutic, Inc. | $379.7M | — (loss-making) | — | — | n/m | −46.69% (below 0%: shrinking) | 0.00% | 0.00% | |
| ALLO Allogene Therapeutics, Inc. | $376.6M | — (loss-making) | — (loss-making) | +20,990.91% (above 0%: growing) | n/m | +17.73% (above 0%: growing) | 100.00% | (1,011.21%) | Compare |
| LYEL Lyell Immunopharma, Inc. | $367.6M | — (loss-making) | — (loss-making) | −80.00% (below 0%: shrinking) | n/m | −21.82% (below 0%: shrinking) | 100.00% | (1,609,833.33%) | Compare |
| CCCC C4 Therapeutics, Inc. | $362.9M | — (loss-making) | — (loss-making) | −24.59% (below 0%: shrinking) | n/m | +17.88% (above 0%: growing) | 100.00% | (290.46%) | Compare |
| ZURA Zura Bio Limited | $358.3M | — (loss-making) | — | — | n/m | −26.22% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $379.9M | — | — | +232.31% | — | −21.82% | 100.00% | (78.02%) |
Pay and ownership Proxy statement filed 24 April 2026
Ownership
Directors and executive officers, together
39.80%
Persons and entities affiliated with Timothy A. Springer, Ph.D.
32.10%
Timothy A. Springer, Ph.D.
32.10%
Entities affiliated with FMR LLC
14.90%
Persons and entities affiliated with TCG Crossover Fund
6.20%
Entities affiliated with Aberdeen Group plc
6.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement